HHT Research Grants

Cure HHT will fund breakthrough research, supporting the best global science to uncover the mechanisms underlying the disease, improve treatment, and ultimately find a cure for Hereditary Hemorrhagic Telangiectasia (also known as Osler-Weber-Rendu Syndrome). The grant recipients listed below were selected with the invaluable assistance of the Cure HHT Scientific Review Committee, comprised of the Cure HHT Scientific Research Director, Chairman of the Cure HHT Global Research and Medical Advisory Board and scientific peer reviewers who generously volunteer their time to Cure HHT.

 

Use the filters below to explore research grants and awards by year and topic:

  • Reset

2017

Hereditary Haemorrhagic Telangiectasia: Novel cardiopulmonary insights

2015

An Innovative Gene Therapy by Selective and Regulative Neutralizing VEGF in HHT-Associated Brain Arteriovenous Malformations

2015

Identification of Genetic Modifiers in HHT

2015

Role of Endoglin in HHT and High Output Heart Failure

2015

Endoglin Regulates Biology and Signal Transduction in Vascular Smooth Muscle Cells

2015

High-Content Deep-Phenotypic Screening of Existing Drugs for the Treatment of HHT

2015

The Role of Macrophages in the Pathogenesis of HHT

2014

Clinical Implications of Pulmonary Shunting on Contrast Echocardiography

2014

A Randomized Controlled Trial of Bevacizumab for HHT-Related Epistaxis

2013

Development of a North American HHT Database

2013

Collaborative Project to Improve Detection Rates of Hereditary Hemorrhagic Telangiectasia in the KPNC Population

2011

In Vivo Cell Biology Approach to Defining the Natural History of HHT-Associated AVMs

2010

North American Study of Epistaxis (NOSE Study)

2008

Molecular Characterization of HHT

2008

Cross-talk between Alk1/ Endoglin and Notch Signaling in HHT

2008

Therapeutic Potential of VEGF Blockade in HHT Pathogenesis

2008

Genetic Modification of HHT Phenotype

2007

Development of a Standardized Epistaxis Severity Score (ESS) in HHT in Order to Validate Therapy Efficacy

2006

Differentiation of Eng-/- Embryonic Stem Cells in Embryoid Bodies, a Paradigm for Vascuaogenesis/ Angiogenesis. Defects in HHT and a Potential Drug Screen

2006

TGF-B Activates eNOS and Regulates Vasomotor Function by an endoglin-and Alk-1 Dependent Mechanism

2005

Identification of Risk Factors for AVM Formation in HHT

2005

Primary Cultures of Endothelial and Monocytic Cells Derived from HHT Patients: An Open Window to Unravel the Pathogeniticy of HHT

2004

Laser Treatment for Nosebleeds: When Is It Likely to Work?

2004

Interferon-2B Treatment in Hereditary Hemorrhagic Telangiectasia